Results 121 to 130 of about 77,108 (288)

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report

Case Reports in Oncology, 2017
Background: Antitumor immunotherapy has become a major player in cancer therapy. Ipilimumab is a humanized monoclonal antibody against the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an important downregulator of T-cell activation.
Reem Akel, Bilal Anouti, Arafat Tfayli
doaj   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

Renal cell carcinoma with atypical omental metastasis: A case report and literature review

UroPrecision, EarlyView.
Abstract Background Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, with common metastatic sites including the lungs, bones, liver, and brain. Omental metastasis is exceedingly rare and usually occurs postoperatively. Fumarate hydratase‐deficient (FH‐deficient) RCC, a recently classified and highly aggressive subtype of ...
Andrew Jing, Zachary Guo, Katherine Wu, Wei Wang, James Jing   +4 more
wiley   +1 more source

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients.
Sandra Aung, Sigrun Hallmeyer, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Ryan J. Sullivan, Marc S. Ernstoff, Brendan D. Curti, Elizabeth I. Buchbinder, Rene Gonzalez, John M. Richart, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Girald P. Miletello, Joe Lutzky, Michael A. Morse   +19 more
doaj   +1 more source

Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Stage IV Melanoma Receiving Immune Checkpoint Inhibitors: A Single‐Center Retrospective Study

The Journal of Dermatology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for malignant melanoma (MM). However, given variable response rates and potential toxicities, identifying robust biomarkers is crucial. We investigated whether the modified Glasgow Prognostic Score (mGPS) predicts treatment efficacy and toxicity in Asian patients with
Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara   +4 more
wiley   +1 more source

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. [PDF]

, 2019
The increasing number of patients with sequenced prostate cancer genomes enables us to study not only individual oncogenic mutations, but also capture the global burden of genomic alterations.
Bose, Rohit, Ryan, Matthew J
core   +1 more source

FOXD3 Regulates VISTA Expression in Melanoma. [PDF]

, 2020
Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets.
Aplin, Andrew E., Berger, Adam C., Chervoneva,, Davies, Michael A., Erkes, Dan A., Fisher, David E., Gershenwald, Jeffrey E., Knecht, Meghan, Lo, Jennifer A., McCue, Peter A., Mollaee, Mehri, Purwin, Timothy J., Rosenbaum, Sheera R., Zhong, Zhijiu   +13 more
core   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study. [PDF]

Liver Int
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Kim JS, Wong J, Chen SC, Tai D, Yang H, Kim Y, Kang B, Kim I, Kim H, An C, Jang SJ, Kudo M, Lim HY, Kim C, Yau T, Chon HJ.   +15 more
europepmc   +2 more sources